These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 19366455)
1. BMP-2 signaling in ovarian cancer and its association with poor prognosis. Le Page C; Puiffe ML; Meunier L; Zietarska M; de Ladurantaye M; Tonin PN; Provencher D; Mes-Masson AM J Ovarian Res; 2009 Apr; 2():4. PubMed ID: 19366455 [TBL] [Abstract][Full Text] [Related]
2. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Presneau N; Mes-Masson AM; Ge B; Provencher D; Hudson TJ; Tonin PN Oncogene; 2003 Mar; 22(10):1568-79. PubMed ID: 12629520 [TBL] [Abstract][Full Text] [Related]
3. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Manderson EN; Mes-Masson AM; Novak J; Lee PD; Provencher D; Hudson TJ; Tonin PN Genome Res; 2002 Jan; 12(1):112-21. PubMed ID: 11779836 [TBL] [Abstract][Full Text] [Related]
4. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Tonin PN; Hudson TJ; Rodier F; Bossolasco M; Lee PD; Novak J; Manderson EN; Provencher D; Mes-Masson AM Oncogene; 2001 Oct; 20(45):6617-26. PubMed ID: 11641787 [TBL] [Abstract][Full Text] [Related]
5. Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. Cody NA; Zietarska M; Filali-Mouhim A; Provencher DM; Mes-Masson AM; Tonin PN BMC Med Genomics; 2008 Aug; 1():34. PubMed ID: 18687136 [TBL] [Abstract][Full Text] [Related]
7. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Zietarska M; Maugard CM; Filali-Mouhim A; Alam-Fahmy M; Tonin PN; Provencher DM; Mes-Masson AM Mol Carcinog; 2007 Oct; 46(10):872-85. PubMed ID: 17455221 [TBL] [Abstract][Full Text] [Related]
8. Cyclin I mRNA expression correlates with kinase insert domain receptor expression in human epithelial ovarian cancer. Cybulski M; Jeleniewicz W; Nowakowski A; Stenzel-Bembenek A; Tarkowski R; Kotarski J; Stepulak A Anticancer Res; 2015 Feb; 35(2):1115-9. PubMed ID: 25667501 [TBL] [Abstract][Full Text] [Related]
9. Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. Manderson EN; Birch AH; Shen Z; Mes-Masson AM; Provencher D; Tonin PN Int J Gynecol Cancer; 2009 May; 19(4):513-25. PubMed ID: 19509545 [TBL] [Abstract][Full Text] [Related]
10. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. Ma Y; Ma L; Guo Q; Zhang S J Exp Clin Cancer Res; 2010 Jun; 29(1):85. PubMed ID: 20587070 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer. Ma Z; Wang X; He J; Xia J; Li Y PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289 [TBL] [Abstract][Full Text] [Related]
12. Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype. Perez-Juarez CE; Arechavaleta-Velasco F; Mendez C; Díaz-Cueto L Med Oncol; 2020 May; 37(7):59. PubMed ID: 32474861 [TBL] [Abstract][Full Text] [Related]
13. Three-Dimensional Cellular Arrangement in Epithelial Ovarian Cancer Cell Lines TOV-21G and SKOV-3 is Associated with Apoptosis-Related miRNA Expression Modulation. de Lima AB; Silva LM; Gonçales NG; Carvalho MRS; da Silva Filho AL; da Conceição Braga L Cancer Microenviron; 2018 Jun; 11(1):85-92. PubMed ID: 29307001 [TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
15. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Gagné JP; Gagné P; Hunter JM; Bonicalzi ME; Lemay JF; Kelly I; Le Page C; Provencher D; Mes-Masson AM; Droit A; Bourgais D; Poirier GG Mol Cell Biochem; 2005 Jul; 275(1-2):25-55. PubMed ID: 16335783 [TBL] [Abstract][Full Text] [Related]
16. Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines. Kwiecińska P; Taubøll E; Grzyb E; Fiedor E; Ptak A; Gregoraszczuk EL Int J Gynecol Cancer; 2016 Nov; 26(9):1546-1556. PubMed ID: 27654264 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway. Zhao J; Liu HR Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076 [TBL] [Abstract][Full Text] [Related]
18. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action. Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129 [TBL] [Abstract][Full Text] [Related]
19. Characterization of three new serous epithelial ovarian cancer cell lines. Ouellet V; Zietarska M; Portelance L; Lafontaine J; Madore J; Puiffe ML; Arcand SL; Shen Z; Hébert J; Tonin PN; Provencher DM; Mes-Masson AM BMC Cancer; 2008 May; 8():152. PubMed ID: 18507860 [TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]